Windtree to Present at the Oppenheimer 31st Annual Healthcare Conference

Rhea-AI Summary

Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced that CEO Craig Fraser will present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 10:40 AM ET. A live audio webcast will be available on Windtree's website, with a replay accessible for 30 days. Windtree is focused on developing therapies for acute cardiovascular and pulmonary disorders, including its lead candidate istaroxime for heart failure and AEROSURF® for respiratory distress in infants. For more details, visit www.windtreetx.com.

WARRINGTON, Pa., March 15, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, president and chief executive officer, will present at the Oppenheimer 31^st Annual Healthcare Conference and be available for 1x1 meetings. Details are as follows:

Oppenheimer 31^st Annual Healthcare Conference
Date:                Tuesday, March 16, 2021
Time:               10:40 AM Eastern Time
Webcast:         To register, click on the link HERE

A live audio webcast will be available via the events page of the Windtree website at http://windtreetx.investorroom.com/events. A replay of the presentation will be archived on the Windtree website for 30 days for those unable to listen live.

About Windtree Therapeutics
Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree has also focused on developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee's HK, while Windtree  evaluates other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions including lung injury due to viral, chemical and radiation induced insults. Also, in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.

For more information, please visit the Company's website at www.windtreetx.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/windtree-to-present-at-the-oppenheimer-31st-annual-healthcare-conference-301246440.html

SOURCE Windtree Therapeutics, Inc.

FAQ

What is the date and time of Windtree's presentation at the Oppenheimer Healthcare Conference?

Windtree Therapeutics will present on March 16, 2021, at 10:40 AM ET.

Where can I watch the Windtree Therapeutics presentation live?

The presentation can be viewed live via the events page on Windtree's website.

What is Windtree Therapeutics' focus in the healthcare sector?

Windtree focuses on developing late-stage interventions for acute cardiovascular and pulmonary disorders.

Who is the CEO of Windtree Therapeutics?

The CEO of Windtree Therapeutics is Craig Fraser.

What is istaroxime, developed by Windtree Therapeutics?

Istaroxime is Windtree's lead candidate aimed at treating acute heart failure.

What is AEROSURF®, and who is it meant for?

AEROSURF® is a non-invasive surfactant treatment for premature infants with respiratory distress syndrome.